Fresenius Catches a Tailwind: Rating Upgrade, Share Conversion, and a Biosimilar Pipeline in Focus
Published on 08/13/2026 at 18:12 | Redaktion boerse-global.de
The health-care group has spent much of the past two years under the hood, simplifying its structure and paying down debt. That work is now starting to show up in places investors tend to notice: credit ratings, earnings guidance, and the share price itself. Over the last 30 days, Fresenius stock has gained 15 percent, closing recently at EUR 47.07 — a run that reflects growing confidence in the company's turnaround story.
A Two-Pronged August Signal
August has brought Fresenius a pair of reinforcing developments. Fitch Ratings lifted its outlook on the company's creditworthiness from "stable" to "positive" while affirming the long-term rating at "BBB-". At the same time, the company is executing a change in its share structure, converting its bearer shares into registered shares — a move approved by shareholders earlier this year that is designed to facilitate more direct communication with investors.
For shareholders, the conversion happens automatically through their depositories. Dividend rights and voting rights remain untouched, and trading on exchanges continues without interruption. The company will maintain a share register going forward.
Fitch's decision reflects the group's disciplined deleveraging under the "#FutureFresenius" strategy. Management expects to bring the leverage ratio — net financial debt to EBITDA — to the lower end of its 2.5x to 3.0x target range by year-end. At 2.6x, the metric already sits comfortably within that corridor, a level Fitch acknowledged in its assessment.
Should investors sell immediately? Or is it worth buying Fresenius?
Guidance Raised, Analysts Respond
The catalyst for the recent share-price momentum came on August 4, when Fresenius lifted its full-year outlook. The company now expects currency-adjusted growth in core earnings per share of 10 to 15 percent, up from a previous range of 5 to 10 percent. The revision was driven by strong operational performance in its two key segments: Kabi and Helios.
The second-quarter numbers, published on August 7, backed up that optimism. Group revenue rose organically by 6 percent to EUR 5,864 million, while currency-adjusted group EBIT before special items climbed 10 percent to EUR 719 million.
The improved guidance triggered a wave of target-price revisions. DZ Bank set its fair value at EUR 58 on August 10 with a "Buy" rating. Morgan Stanley followed the same day, lifting its target from EUR 49 to EUR 52 while maintaining "Overweight". UBS then raised its target to EUR 56 on August 12, with analyst Graham Doyle pointing to the second quarter as a potential turning point for the group.
Kabi: The Growth Engine, With a Few Bumps
Fresenius Kabi remains the group's most consistent growth driver. The infusion and biosimilars division is now expected to deliver an EBIT margin at the upper end of its 16.5 to 17.0 percent range for 2026 — a level it has already reached, hitting 17 percent. The hospital chain Helios is also growing at a double-digit clip, particularly in Germany and Spain.
On the regulatory front, Kabi announced FDA approval of a rituximab biosimilar for the US market on August 7, and regulatory filings for a vedolizumab biosimilar candidate were accepted by both the FDA and the EMA.
Not everything is smooth sailing, however. The division initiated a recall in the US of one batch of Tyenne (tocilizumab-aazg) in the 400-mg/20-mL vial version due to the risk of glass particles.
Fresenius at a turning point? This analysis reveals what investors need to know now.
Capital Efficiency and the Broader Picture
Return on invested capital (ROIC), a key management metric, has risen by roughly 200 basis points since the restructuring began in 2022, reaching 6.9 percent at the end of the first half. That improvement reflects a sharper focus on core operations and a leaner corporate structure — a narrative reinforced by both the share conversion and the improved credit outlook.
The group's associated company, Fresenius Medical Care, in which Fresenius holds around 32 percent, also delivered encouraging news: profit growth accelerated to 23 percent in the second quarter, and Cassie McLean was appointed to the board as head of Care Delivery.
With a market capitalization of roughly EUR 26.5 billion, Fresenius now finds itself in the relatively comfortable position where operational progress, improved credit metrics, and positive analyst sentiment are all moving in the same direction. The question for investors is whether the stock's recent run has already priced in the good news — or whether the Kabi pipeline and continued deleveraging have more upside to offer.
Ad
Fresenius Stock: New Analysis - 13 August
Fresh Fresenius information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
